X4 Pharmaceuticals Inc
XFOR3.600USD
-0.060-1.64%
Close 12/19, 16:00（ET）Quotes delayed by 15 min
90.53MMarket Cap
LossP/E TTM
More Details of X4 Pharmaceuticals Inc Company
X4 Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on discovering and developing novel therapeutics for the treatment of rare diseases and those with limited treatment options, with a focus on conditions resulting from dysfunction of the immune system. Its lead clinical candidate is mavorixafor, a small-molecule selective antagonist of chemokine receptor CXCR4. It has developed a small-molecule, oral antagonists of the chemokine receptor C-X-C receptor type 4 (CXCR4). It has two pre-clinical candidates: X4P-003, a second-generation CXCR4 antagonist designed to have enhanced properties relative to mavorixafor, potentially enabling opportunities in CXCR4-dependent disorders and primary immunodeficiencies, and X4P-002, a CXCR4 antagonist with a distribution profile and a demonstrated ability to cross the blood-brain barrier.
X4 Pharmaceuticals Inc Info
Ticker SymbolXFOR
Company nameX4 Pharmaceuticals Inc
IPO dateNov 16, 2017
CEO- -
Number of employees143
Security typeOrdinary Share
Fiscal year-endNov 16
Address61 North Beacon Street
CityBOSTON
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code02134
Phone18575298300
Websitehttps://www.x4pharma.com/
Ticker SymbolXFOR
IPO dateNov 16, 2017
CEO- -
Company Executives of X4 Pharmaceuticals Inc
Name
Name/Position
Position
Shareholding
Change
Mr. John Volpone
Mr. John Volpone
President, Chief Operating Officer
President, Chief Operating Officer
289.88K
--
Mr. Michael S. Wyzga
Mr. Michael S. Wyzga
Lead Independent Director
Lead Independent Director
5.56K
+36.98%
Dr. Gary J. Bridger, Ph.D.
Dr. Gary J. Bridger, Ph.D.
Director
Director
4.72K
+46.55%
Dr. Adam Raymond Craig, M.D., Ph.D.
Dr. Adam Raymond Craig, M.D., Ph.D.
Executive Chairman of the Board, Principal Executive Officer
Executive Chairman of the Board, Principal Executive Officer
--
--
Mr. David H. Kirske
Mr. David H. Kirske
Chief Financial Officer, Secretary
Chief Financial Officer, Secretary
--
--
Dr. Murray W. Stewart, M.D.
Dr. Murray W. Stewart, M.D.
Director
Director
--
--
Mr. Daniel Ferry
Mr. Daniel Ferry
Managing Director
Managing Director
--
--
Ms. Francoise De Craecker
Ms. Francoise De Craecker
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. John Volpone
Mr. John Volpone
President, Chief Operating Officer
President, Chief Operating Officer
289.88K
--
Mr. Michael S. Wyzga
Mr. Michael S. Wyzga
Lead Independent Director
Lead Independent Director
5.56K
+36.98%
Dr. Gary J. Bridger, Ph.D.
Dr. Gary J. Bridger, Ph.D.
Director
Director
4.72K
+46.55%
Dr. Adam Raymond Craig, M.D., Ph.D.
Dr. Adam Raymond Craig, M.D., Ph.D.
Executive Chairman of the Board, Principal Executive Officer
Executive Chairman of the Board, Principal Executive Officer
--
--
Mr. David H. Kirske
Mr. David H. Kirske
Chief Financial Officer, Secretary
Chief Financial Officer, Secretary
--
--
Dr. Murray W. Stewart, M.D.
Dr. Murray W. Stewart, M.D.
Director
Director
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Mon, Nov 17
Updated: Mon, Nov 17
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Perceptive Advisors LLC
6.76%
New Enterprise Associates (NEA)
3.70%
Bain Capital Life Sciences Investors, LLC
2.79%
Empery Asset Management, L.P.
2.73%
BVF Partners L.P.
2.55%
Other
81.46%
Shareholders
Shareholders
Proportion
Perceptive Advisors LLC
6.76%
New Enterprise Associates (NEA)
3.70%
Bain Capital Life Sciences Investors, LLC
2.79%
Empery Asset Management, L.P.
2.73%
BVF Partners L.P.
2.55%
Other
81.46%
Shareholder Types
Shareholders
Proportion
Hedge Fund
9.37%
Private Equity
6.97%
Investment Advisor
6.47%
Investment Advisor/Hedge Fund
4.47%
Venture Capital
3.70%
Individual Investor
1.17%
Research Firm
0.03%
Other
67.80%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
203
11.99M
31.56%
+7.22M
2025Q2
221
3.50M
59.08%
-1.79M
2025Q1
225
3.45M
58.17%
-2.00M
2024Q4
216
103.66M
60.78%
-53.08M
2024Q3
212
110.90M
65.83%
-43.36M
2024Q2
209
114.19M
68.28%
-40.11M
2024Q1
203
115.38M
69.15%
-30.64M
2023Q4
192
109.42M
65.98%
-32.86M
2023Q3
189
132.64M
89.63%
+450.20K
2023Q2
191
133.25M
115.52%
+52.30M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
New Enterprise Associates (NEA)
2.23M
19.58%
+1.73M
+347.14%
Aug 13, 2025
Bain Capital Life Sciences Investors, LLC
495.99K
4.35%
--
--
Sep 09, 2025
BVF Partners L.P.
2.23M
19.58%
+2.23M
--
Aug 13, 2025
Trails Edge Capital Partners LP
1.57M
13.77%
+1.57M
--
Aug 11, 2025
Deep Track Capital LP
1.12M
9.84%
+1.12M
--
Aug 19, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
ProShares UltraPro Russell2000
0%
iShares Russell 2000 Value ETF
0%
ProShares Hedge Replication ETF
0%
Proshares Ultra Russell 2000
0%
Vanguard US Momentum Factor ETF
0%
iShares Micro-Cap ETF
0%
Global X Russell 2000 Covered Call ETF
0%
iShares Russell 3000 ETF
0%
Global X Russell 2000 ETF
0%
iShares Russell 2000 Growth ETF
0%
View more
ProShares UltraPro Russell2000
Proportion0%
iShares Russell 2000 Value ETF
Proportion0%
ProShares Hedge Replication ETF
Proportion0%
Proshares Ultra Russell 2000
Proportion0%
Vanguard US Momentum Factor ETF
Proportion0%
iShares Micro-Cap ETF
Proportion0%
Global X Russell 2000 Covered Call ETF
Proportion0%
iShares Russell 3000 ETF
Proportion0%
Global X Russell 2000 ETF
Proportion0%
iShares Russell 2000 Growth ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Apr 24, 2025
Merger
30→1
Date
Type
Ratio
Apr 24, 2025
Merger
30→1
FAQs
Who are the top five shareholders of X4 Pharmaceuticals Inc?
The top five shareholders of X4 Pharmaceuticals Inc are:
New Enterprise Associates (NEA) holds 2.23M shares, accounting for 19.58% of the total shares.
Bain Capital Life Sciences Investors, LLC holds 495.99K shares, accounting for 4.35% of the total shares.
BVF Partners L.P. holds 2.23M shares, accounting for 19.58% of the total shares.
Trails Edge Capital Partners LP holds 1.57M shares, accounting for 13.77% of the total shares.
Deep Track Capital LP holds 1.12M shares, accounting for 9.84% of the total shares.
New Enterprise Associates (NEA) holds 2.23M shares, accounting for 19.58% of the total shares.
Bain Capital Life Sciences Investors, LLC holds 495.99K shares, accounting for 4.35% of the total shares.
BVF Partners L.P. holds 2.23M shares, accounting for 19.58% of the total shares.
Trails Edge Capital Partners LP holds 1.57M shares, accounting for 13.77% of the total shares.
Deep Track Capital LP holds 1.12M shares, accounting for 9.84% of the total shares.
What are the top three shareholder types of X4 Pharmaceuticals Inc?
The top three shareholder types of X4 Pharmaceuticals Inc are:
Perceptive Advisors LLC
New Enterprise Associates (NEA)
Bain Capital Life Sciences Investors, LLC
Perceptive Advisors LLC
New Enterprise Associates (NEA)
Bain Capital Life Sciences Investors, LLC
How many institutions hold shares of X4 Pharmaceuticals Inc (XFOR)?
As of 2025Q3, 203 institutions hold shares of X4 Pharmaceuticals Inc, with a combined market value of approximately 11.99M, accounting for 31.56% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -27.52%.
What is the biggest source of revenue for X4 Pharmaceuticals Inc?
In --, the -- business generated the highest revenue for X4 Pharmaceuticals Inc, amounting to -- and accounting for --% of total revenue.
